Laboratory News and Research

RSS

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

Mary Lee's primary care physician is also a family friend. When he walked into the exam room in October 2006 with tears in his eyes, she knew something serious was wrong. But she was shocked to learn she had a brain tumor - and later found out it was the most aggressive malignant type, a glioblastoma multiforme.

14 Oct 2010

'Brain-computer interface' development receives Arizona Biomedical Research Commission grant

Efforts to advance technology to aid people who have lost communication and movement abilities are getting support from an Arizona Biomedical Research Commission grant for a project combining resources and expertise at Arizona State University and the Children's Neuroscience Institute at Phoenix Children's Hospital.

14 Oct 2010

U.S. DoD awards five-year grant to study blast wave’s effects on brain neural circuitry

A team of biomedical engineers from Columbia University, University of Pennsylvania, and Duke University has been awarded a $6.25 million dollar, five-year Multi University Research Initiative (MURI) grant from the U.S. Department of Defense to study the effects of blast waves on the neural circuitry of the brain.

14 Oct 2010

Dangers of over the counter 'natural' slimming products

The desire for a quick-fix for obesity fuels a lucrative market in so-called natural remedies. But a study of medical records in Hong Kong revealed 66 cases where people were suspected to have been poisoned by a "natural" slimming therapy. In eight cases the people became severely ill, and in one case the person died. The study is published today in the British Journal of Clinical Pharmacology.

14 Oct 2010

World's third rectal microbicide trial launched in Pittsburgh

The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.

14 Oct 2010

Stony Brook professor receives 2010 NIH Director's New Innovator Award

Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award.

14 Oct 2010

Stony Brook professor receives NIH grant to optimize cardiovascular devices

Danny Bluestein, Ph.D., Professor of Biomedical Engineering at Stony Brook University, has been awarded a five-year, $7.5 million grant by the National Institutes of Health. The award marks the first time a Stony Brook professor has received a Phase II Quantum Grant, given by The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the NIH, to make a profound improvement or quantum leap forward—in health care.

14 Oct 2010

Stimulating brain's nicotine receptors may eliminate side effects of Alzheimer's drug: Research

A team of neuroscientists has discovered important new information in the search for an effective treatment for Alzheimer's disease, the debilitating neurological disorder that afflicts more than 5.3 million Americans and is the sixth-leading cause of death in the United States. Hey-Kyoung Lee, associate professor in the University of Maryland Department of Biology, and her research team have shown that they may be able to eliminate debilitating side effects caused by a promising Alzheimer's drug by stimulating the brain's nicotine receptors.

14 Oct 2010

OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

Global ophthalmic device company OptiMedica Corp. has announced that its Catalys Precision Laser System will be featured as part of four clinical presentations at the American Academy of Ophthalmology annual meeting in Chicago on October 16, 17 and 18.

13 Oct 2010

MEDTOX Scientific third quarter total revenues increase 15.9% to $25.8 million

MEDTOX Scientific, Inc. today announced results for the third quarter ended September 30, 2010. MEDTOX achieved record revenues and gross profit in the quarter.

13 Oct 2010

New York Stem Cell Foundation names first six NYSCF Investigators

In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.

13 Oct 2010

PAXX100 audio device improves quality of life of people with tinnitus

Tinnitus Laboratory today announced the results of a clinical study that shows significant improvements from the use of PAXX100, a customized audio device for tinnitus management designed for long-term reduction of tinnitus perception.

13 Oct 2010

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.

13 Oct 2010

Study compares minimally invasive and open surgeries for lower back pain

Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.

13 Oct 2010

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Urgent Care Association of America certifies eighteen more facilities

Eighteen more facilities have just received the Certified Urgent Care Center designation awarded by the Urgent Care Association of America. The Certified Urgent Care program helps the public identify urgent care centers and promotes and advances the urgent care industry.

13 Oct 2010

NCI rates Abramson Cancer Center as 'exceptional'

The University of Pennsylvania's Abramson Cancer Center has been rated as "exceptional" by the National Cancer Institute (NCI) during a competitive research funding review by the government agency.

13 Oct 2010

Researchers develop new therapy to overcome tissue incompatibility in kidney transplantation

Donor kidneys can be successfully transplanted even if there is strong tissue incompatibility between donor and recipient. An interdisciplinary working group headed by Dr. Christian Morath, senior consultant at the Department of Nephrology at Heidelberg University Hospital (Medical Director: Professor Dr. Martin Zeier) and Professor Dr. Caner S-sal, head of antibody laboratory in the Department of Transplantation Immunology, showed in a study of 34 sensitized high-risk patients that the success rate in these patients was not different from the success rate of patients with a low immunological risk.

13 Oct 2010